| ￥3300 | |
| Z05304-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 36.47 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 47-57 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of Fibronectin (1266-1356) hFc Chimera, Human is greater than 95% as determined by SEC-HPLC. »
Fibronectin (1266-1356) hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Fibronectin is a high molecular glycoprotein present in the blood, connective tissue and at cell surface. It is synthesized by many types of differentiated cells and is believed to be involved in the attachment of cells to the surrounding extracellular matrix. Fibronectin has affinity to the other main components of extracellular matrix, collagen and glycosaminoglycans. |
| Synonyms | FN; CIG; FN1; ED-B; FINC; FNZ; GFND; GFND2; LETS; MSF; SMDCF |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
